Just a month after picking an accelerated review by U.S. regulators for its new blockbuster drug Hemlibra, Roche has now reported new data from two clinical trials that state the drug effectively cut down the bleeding episodes on patients with Hemophilia A for whom blood does not clot due to their genetic disorder.
Roche bets big on its new drug Hemlibra and anticipates it to be a huge revenue driver. Hemlibra is anticipated to make up for the declining revenue for the drugs that are out of patent, mainly its oncology drugs.
https://news.alphastreet.com/roches-latest-trials-prove-wider-use-of-new-drug-hemlibra/
Roche bets big on its new drug Hemlibra and anticipates it to be a huge revenue driver. Hemlibra is anticipated to make up for the declining revenue for the drugs that are out of patent, mainly its oncology drugs.
https://news.alphastreet.com/roches-latest-trials-prove-wider-use-of-new-drug-hemlibra/